The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Cancer of the ovary, fallopian tube, and peritoneum
Open accessAbstract
The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high‐grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now “microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node” metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Siegel, R., Ward, E., Brawley, O., & Jemal, A. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20121 · Cited by 4,070
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
WHO classification of tumours of female reproductive organs
Kurman, R. J., Carcangiu, M. L., Herrington, C. S., & Young, R. H. (2014) · International Agency for Research on Cancer eBooks · Cited by 1,966
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Self-citationCarboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Self-citationColeman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Self-citationOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Self-citationLedermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Self-citationAghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 933
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 916
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Inherited Mutations in Women With Ovarian Carcinoma
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Yi, Q., Burger, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5495 · Cited by 769
Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1684 · Cited by 705
Self-citationvan der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321002 · Cited by 705
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Trimbos, J. B., Vergote, I., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.113 · Cited by 674
Granulosa Cell Tumor of the Ovary
Schumer, S. T., & Cannistra, S. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.019 · Cited by 674
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., & Major, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221501 · Cited by 583
The distal fallopian tube: a new model for pelvic serous carcinogenesis
Crum, C. P., Drapkin, R., Miron, A., Ince, T. A., Muto, M., Kindelberger, D. W., & Lee, Y. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328011a21f · Cited by 512
Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2622 · Cited by 485
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Panici, P. B., Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K., Winter, R., Pellegrino, A., Greggi, S., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji102 · Cited by 465
Primary cytoreductive surgery for epithelial ovarian cancer.
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983) · PubMed · Cited by 437
Self-citationZanetta, G., Rota, S., Chiari, S., Bonazzi, C., Bratina, G., & Mangioni, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2658 · Cited by 420
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Rose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.405 · Cited by 386
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
Clinical Features of Hypersensitivity Reactions to Carboplatin
Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., & Belinson, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1141 · Cited by 365
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Chi, D. S., McCaughty, K., Diaz, J. P., Huh, J., Schwabenbauer, S., Hummer, A. J., Venkatraman, E. S., Aghajanian, C., Sonoda, Y., Abu‐Rustum, N. R., et al. (2006) · Cancer · doi:10.1002/cncr.21845 · Cited by 350
Carlson, J. W., Miron, A., Jarboe, E. A., Parast, M. M., Hirsch, M. S., Lee, Y., Muto, M. G., Kindelberger, D., & Crum, C. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4814 · Cited by 347
Management of Ovarian Stromal Cell Tumors
Colombo, N., Parma, G., Zanagnolo, V., & Insinga, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1005 · Cited by 326
Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323
Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., & Spirtos, N. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.013 · Cited by 307
Böhm, S., Faruqi, A., Said, I., Lockley, M., Brockbank, E., Jeyarajah, A., Fitzpatrick, A., Ennis, D., Dowe, T., Santos, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.5212 · Cited by 303
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
Gershenson, D. M., Sun, C. C., Bodurka, D., Coleman, R. L., Lu, K. H., Sood, A. K., Deavers, M., Malpica, A. L., & Kavanagh, J. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.001 · Cited by 291
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer
Burghardt, E., Girardi, F., Lahousen, M., Tamussino, K., & Stettner, H. (1991) · Gynecologic Oncology · doi:10.1016/0090-8258(91)90099-q · Cited by 285
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2018) · JAMA · doi:10.1001/jama.2017.21926 · Cited by 283
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
Gershenson, D. M., Bodurka, D. C., Coleman, R. L., Lu, K. H., Malpica, A., & Sun, C. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0632 · Cited by 279
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.183 · Cited by 262
Shapiro, J. D., Millward, M. J., Rischin, D., Michael, M., Walcher, V., Francis, P. A., & Toner, G. C. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0284 · Cited by 250
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Schmeler, K. M., Sun, C. C., Bodurka, D. C., T. Deavers, M., Malpica, A., Coleman, R. L., Ramirez, P. T., & Gershenson, D. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.013 · Cited by 245
Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer
Menon, U., Skates, S. J., Lewis, S., Rosenthal, A. N., Rufford, B., Sibley, K., MacDonald, N., Dawnay, A., Jeyarajah, A., Bast, R. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6642 · Cited by 243
Advanced Ovarian Cancer Trialists' Group, Aabo, K., Adams, M., Adnitt, P., Alberts, D., Athanazziou, A., Barley, V, Bell, D., Bianchi, U., Bolis, G., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.710 · Cited by 234
Grabowski, J. P., Harter, P., Heitz, F., Pujade-Lauraine, E., Reuss, A., Kristensen, G., Ray-Coquard, I., Heitz, J., Traut, A., Pfisterer, J., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.01.022 · Cited by 233
Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8566 · Cited by 229
Clinical Trials in Recurrent Ovarian Cancer
Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb8aa · Cited by 224
Self-citationA Genetic Epidemiological Study of Carcinoma of the Fallopian Tube
Aziz, S., Kuperstein, G., Rosen, B., Cole, D., Nedelcu, R., McLaughlin, J., & Narod, S. A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6095 · Cited by 222
BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas
Wong, K.-K., Tsang, Y. T. M., Deavers, M. T., Mok, S. C., Zu, Z., Sun, C., Malpica, A., Wolf, J. K., Lu, K. H., & Gershenson, D. M. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100212 · Cited by 220
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
Gershenson, D. M., Sun, C. C., Iyer, R. B., Malpica, A. L., Kavanagh, J. J., Bodurka, D. C., Schmeler, K., & Deavers, M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.02.037 · Cited by 210
Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M. C., Fossati, R., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.307 · Cited by 189
Du Bois, A., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Jensen, P. T., Selle, F., Guyon, F., Pomel, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5501 · Cited by 176
Kennedy, A. W., & Hart, W. R. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960715)78:2<278::aid-cncr14>3.0.co;2-t · Cited by 175
Negri, E., Franceschi, S., Tzonou, A., Booth, M., La Vecchia, C., Parazzini, F., Beral, V., Boyle, P., & Trichopoulos, D. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490110 · Cited by 167
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
Hoskins, P. J., & Swenerton, K. D. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.60 · Cited by 166
Committee Opinion No. 620: Salpingectomy for Ovarian Cancer Prevention
(2015) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000459871.88564.09 · Cited by 163
Symptoms associated with diagnosis of ovarian cancer: a systematic review
Bankhead, C. R., Kehoe, S. T., & Austoker, J. (2005) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2005.00572.x · Cited by 161
Self-citationReclassification of serous ovarian carcinoma by a 2‐tier system: A Gynecologic Oncology Group Study
Bodurka, D. C., Deavers, M. T., Tian, C., Sun, C. C., Malpica, A., Coleman, R. L., Lu, K. H., Sood, A. K., Birrer, M. J., Ozols, R., et al. (2012) · Cancer · doi:10.1002/cncr.26618 · Cited by 160
Gilbert, L., Basso, O., Sampalis, J. S., Karp, I., Martins, C., Feng, J., Piedimonte, S., Quintal, L., Ramanakumar, A. V., TAKEFMAN, J. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70333-3 · Cited by 155
Chan, J. K., Tian, C., Fleming, G. F., Monk, B. J., Herzog, T. J., Kapp, D. S., & Bell, J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.073 · Cited by 148
Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas
Hsu, C., Bristow, R. E., Cha, M. S., Wang, B. G., Ho, C., Kurman, R. J., Wang, T., & Shih, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0893 · Cited by 148
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression
Roh, M. H., Yassin, Y., Miron, A., Mehra, K. K., Mehrad, M., Monte, N. M., Mutter, G. L., Nucci, M. R., Ning, G., McKeon, F., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.119 · Cited by 137
Friedlander, M. L., Millward, M., Bell, D., Bugat, R., Harnett, P. R., Moreno, J. A., Campbell, L., Varette, C., Ripoche, V., & Kayitalire, L. (1998) · Annals of Oncology · doi:10.1023/a:1008469212268 · Cited by 137
Self-citationCurrent Update on Borderline Ovarian Neoplasms
Lalwani, N., Shanbhogue, K., Vikram, R., Nagar, A. M., Jagirdar, J. S., & Prasad, S. R. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.3936 · Cited by 130
Testicular germ cell tumors: pathogenesis, diagnosis and treatment
Winter, C., & Albers, P. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.196 · Cited by 125
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
Tay, E. H. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)01977-4 · Cited by 124
Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases
Gilks, C. B., Irving, J., Köbel, M., Lee, C., Singh, N., Wilkinson, N. S., & McCluggage, W. G. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000353 · Cited by 123
Colombo, N., Kutarska, E., Dimopoulos, M. A., Bae, D., Rzepka-Górska, I., Bidziński, M., Scambia, G., Engelholm, S. A., Joly, F., Weber, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8082 · Cited by 122
Management of Platinum-Sensitive Recurrent Ovarian Cancer
Pfisterer, J., & Ledermann, J. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.012 · Cited by 121
Calculator for ovarian carcinoma subtype prediction
Kalloger, S. E., Köbel, M., Leung, S. C. Y., Mehl, E., Gao, D., Marcon, K. M., Chow, C., Clarke, B. A., Huntsman, D. D., & Gilks, C. B. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.215 · Cited by 111
Tamoxifen for relapse of ovarian cancer
Williams, C., Simera, I., & Bryant, A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001034.pub2 · Cited by 108
Fader, A. N., Bergstrom, J., Jernigan, A. M., Tanner, E. J., Roche, K. L., Stone, R. L., Levinson, K. L., Ricci, S., Wethingon, S., Wang, T., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.127 · Cited by 102
Geerts, I. S., Vergote, I., Neven, P., & Billen, J. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a702d1 · Cited by 95
Ayhan, A., Kurman, R. J., Yemelyanova, A. V., VANG, R. S., Logani, S., Seidman, J. D., & Shih, I. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181a24354 · Cited by 92
Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States
Fuh, K. C., Shin, J. Y., Kapp, D. S., Brooks, R. A., Ueda, S. M., Urban, R. R., Chen, L.-M., & Chan, J. K. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.009 · Cited by 78
Hurteau, J. A., Brady, M. F., Darcy, K. M., McGuire, W. P., Edmonds, P. R., Pearl, M. L., Ivanov, I., Tewari, K. S., Mannel, R. S., Zanotti, K. M., et al. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.08.002 · Cited by 73
Chemotherapy for Advanced Germ Cell Tumors
Kondagunta, G. V., & Motzer, R. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.7882 · Cited by 72
Vasey, P. A., Paul, J., Birt, A., Junor, E., Reed, N. S., Symonds, R. P., Rj, A., Graham, J., Crawford, S. M., Coleman, R. E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2069 · Cited by 71
Hereditary ovarian cancer: Heterogeneity in age at onset
Lynch, H. T., Watson, P. A., Lynch, J. F., Conway, T., & Fili, M. (2010) · Cancer · doi:10.1002/cncr.2820710213 · Cited by 58
Coghlan, E., Meniawy, T. M., Munro, A., Bulsara, M. K., Stewart, C. J. R., Tan, A. L. Y., Koay, M. H. E., MaGee, D., Codde, J., Tan, J., et al. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000945 · Cited by 52
Clamp, A. R., McNeish, I. A., Dean, A. P., Gallardo, D., Weon-Kim, J., O’Donnell, D. M., Hook, J., Coyle, C., Blagden, S. P., Brenton, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.039 · Cited by 51
Treatment of malignant ovarian germ cell tumors with preservation of fertility: A report of 28 cases
Wu, P.-C., Huang, R.-L., Lang, J., Huang, H., Lian, L., & Tang, M.-Y. (1991) · Gynecologic Oncology · doi:10.1016/0090-8258(91)90074-f · Cited by 42
Targeted therapy for gynecologic cancers: Toward the era of precision medicine
Basu, P. S., Mukhopadhyay, A., & Konishi, I. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12620 · Cited by 23
(2000) · doi:10.1002/1097-0142(20000715)89:2
Cited by
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Self-citationHe, Y., Li, T., Liu, J., Ou, Q., & Zhou, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-6609-x · Cited by 11
Metadata
- Authors
- Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M.
- Venue
- International Journal of Gynecology & Obstetrics
- Publisher
- Wiley
- Published
- 2018-10
- Volume
- 143
- Issue
- S2
- Pages
- 59-78
- ISSN
- 0020-6695 (ISSN-L)
- 0020-7292
- 1879-3479
- OpenAlex
- W4210962013
- Cited by
- 327
- References
- 108
- FWCI
- 27.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.